View the full list of funds available
Our online eligibility checklist helps you see which type of
finance might be right for your business.
A company which has invented a device to help diagnose a heart
condition affecting up to half a million people in the UK has
secured a £50,000 investment from The North West Fund for
Rapid Rhythm Ltd, based in the MedTECH
Centre on Manchester Science Parks, received the £50,000 Pathfinder
investment from The North West Fund for Biomedical, managed by
SPARK Impact. The funding will be used to develop its hand-held
device that uses Electro Cardio Graph (ECG) data to diagnose Atrial
The North West Fund for Biomedical is
a sub-fund of the £185m evergreen North West Fund that is jointly
financed by the European Regional Development Fund and the European
AF is a condition that causes an
irregular and often abnormally-fast heart rate and is traditionally
diagnosed by carrying out an ECG, which involves applying a number
of electrodes to the skin to measure the electrical activity of the
Rapid Rhythm Ltd, a spin-out from the
Central Manchester University Hospitals NHS Foundation Trust, in
collaboration with TRUSTECH Smart Healthcare Ventures, can diagnose
AF using the electrode device which means the ECG examination is
far quicker and could be performed in the primary health care
This round of investment will be used
to further optimise the design of the current device through
refining the electrode interfaces to help improve the accuracy of
It also means Rapid Rhythm will be
able to make prototypes, run trials and gather data needed to get
the device approved.
Dr Adam Fitzpatrick, consultant
cardiologist and inventor of the device, said: "AF carries with it
a high risk factor for stroke, which is the third largest cause of
death in the UK and many other Western countries.
"For patients with AF, their risk of stroke can be substantially
reduced using anticoagulant drugs but there is currently no device
available which enables healthcare professionals to quickly test
patients for the presence of AF, prescribe anti-coagulants and
reduce the incidence of stroke.
"I would like to thank The North
West Fund for Biomedical and SPARK Impact for their
investment into Rapid Rhythm. It is a very exciting time and we are
really pleased they are on board."
Dr Penny Attridge, senior investment
director at SPARK Impact and manager of The North West Fund for
Biomedical, said: "We expect great things from the team and they
have an excellent support network in place with the Central
Manchester University Hospitals NHS Foundation Trust and TRUSTECH
Smart Healthcare Ventures assisting them."
Rapid Rhythm is the
12th Pathfinder investment for The
North West Fund for Biomedical and its
17th investment to date.
Sign up for our newsletter